摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-3-甲基-3-戊烯-2-酮 | 1113-62-8

中文名称
4-氨基-3-甲基-3-戊烯-2-酮
中文别名
——
英文名称
4-amino-3-methylpent-3-en-2-one
英文别名
3-methyl-4-amino-3-penten-2-one;4-Amino-3-methyl-pent-3-en-2-on
4-氨基-3-甲基-3-戊烯-2-酮化学式
CAS
1113-62-8
化学式
C6H11NO
mdl
MFCD00154278
分子量
113.159
InChiKey
RNPWMFDBIICHCI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    8
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    43.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2922399090

SDS

SDS:f2dfd14942b590aba24ae428784ff6a6
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Photocycloaddition of aromatic and aliphatic aldehydes to isoxazoles: Cycloaddition reactivity and stability studies
    作者:Axel G Griesbeck、Marco Franke、Jörg Neudörfl、Hidehiro Kotaka
    DOI:10.3762/bjoc.7.18
    日期:——
    The first photocycloadditions of aromatic and aliphatic aldehydes to methylated isoxazoles are reported. The reactions lead solely to the exo-adducts with high regio- and diastereoselectivities. Ring methylation of the isoxazole substrates is crucial for high conversions and product stability. The 6-arylated bicyclic oxetanes 9a-9c were characterized by X-ray structure analyses and showed the highest
    报道了芳香族和脂肪族醛对甲基化异恶唑的首次光环加成反应。该反应仅导致具有高区域选择性和非对映选择性的外加合物。异恶唑底物的环甲基化对于高转化率和产品稳定性至关重要。6-芳基化双环氧杂环丁烷 9a-9c 通过 X 射线结构分析表征并显示出最高的热稳定性。由异恶唑形成的所有氧杂环丁烷都对酸高度敏感且热不稳定。对原始底物的裂解占主导地位,异恶唑衍生的氧杂环丁烷显示 T 型光致变色。
  • [EN] CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE<br/>[FR] CERTAINES PYRIMIDINES SUBSTITUÉES, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
    申请人:BIOGEN IDEC INC
    公开号:WO2010117425A1
    公开(公告)日:2010-10-14
    Provided are certain Hsp90 inhibitors, i.e., compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use and preparation.
    提供了某些Hsp90抑制剂,即Formula I的化合物及其药用盐、药物组合物以及它们的使用和制备方法。
  • METHOD FOR THE PREPARATION OF 3-FLUOROALKYL-1-METHYLPYRAZOL-4-CARBOXYLIC ACID
    申请人:SOLVAY FLUOR GmbH
    公开号:US20180273486A1
    公开(公告)日:2018-09-27
    The present invention relates to method for the preparation of 3-fluoroalkyl-1-methylpyrazol-4-carboxylic acid, wherein it comprises the following steps: step 1, fluoroacetyl fluoride derivative shown in Formula I undergoes condensation with dimethylamino vinyl methyl ketone, as a result, 3-dimethylamino methylene-fluoro-2,4-pentanedione derivative shown in Formula II is formed; step 2, ring closing reaction takes place between said 3-dimethylamino methylene-fluoro-2,4-pentanedione shown in Formula II and methylhydrazine, in this way, 3-fluoroalkyl-1-methyl-4-acetyl pyrazol derivative shown in Formula III is obtained; step 3, the said 3-fluoroalkyl-1-methyl-4-acetyl pyrazol derivative shown in Formula III is oxidized in the presence of alkali, and then acidified, in this way, 3-fluoroalkyl-1-methylpyrazol-4-carboxylic acid shown in Formula IV is formed. Preparing method of present invention, wherein the required preparing route is simple, the raw material cost is low, the resulting yield of each step is high, and it is suitable for industrialization.
    本发明涉及一种制备3-氟烷基-1-甲基吡唑-4-羧酸的方法,其中包括以下步骤:步骤1,式I所示的氟乙酰氟衍生物与二甲基氨基乙烯基甲基酮发生缩合反应,从而形成式II所示的3-二甲基氨基亚甲基-氟-2,4-戊二酮衍生物;步骤2,式II所示的3-二甲基氨基亚甲基-氟-2,4-戊二酮与甲基肼发生环合反应,得到式III所示的3-氟烷基-1-甲基-4-乙酰吡唑衍生物;步骤3,式III所示的3-氟烷基-1-甲基-4-乙酰吡唑衍生物在碱的存在下被氧化,然后酸化,从而形成式IV所示的3-氟烷基-1-甲基吡唑-4-羧酸。本发明的制备方法,所需制备路线简单,原料成本低,每个步骤的产率高,适合工业化生产。
  • [EN] 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES FOR TREATING NEUROLOGICAL AND NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 5,7-DIHYDRO-PYRROLO-PYRIDINE POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET NEURODÉGÉNÉRATIVES
    申请人:PFIZER
    公开号:WO2018002760A1
    公开(公告)日:2018-01-04
    The present invention provides, in part, compounds of Formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    本发明部分提供了Formula (I)的化合物:或其N-氧化物,或该化合物或N-氧化物的药用盐,其中:R1、R2、L、A和E如本文所述;用于制备的过程;用于制备的中间体;以及含有这种化合物、N-氧化物或盐的组合物,以及它们用于治疗M4介导的(或M4相关的)疾病,例如阿尔茨海默病、精神分裂症(例如其认知和消极症状)、疼痛、成瘾和睡眠障碍。
  • Molecular structure and intramolecular hydrogen bond strength of 3-methyl-4-amino-3-penten-2-one and its N Me and N-Ph substitutions by experimental and theoretical methods
    作者:Seyedabdollah Seyedkatouli、Mohammad Vakili、Sayyed Faramarz Tayyari、Poul Erik Hansen、Fadhil S. Kamounah
    DOI:10.1016/j.molstruc.2019.02.007
    日期:2019.5
    spectroscopy, and X-ray crystallographic methods. The mentioned results were compared to those of 4-amino-3-penten-2-one, APO. DFT calculations suggest a relatively strong intramolecular hydrogen bond in 3-MeAPO and its N Me and N-Ph substituted derivatives with N⋯O distances of 2.597, 2.584, and 2.581 A, and calculated hydrogen bond energies of about 10.9, 13.6, and 14.9 kcal/mol in 3-MeAPO, 3-Me-MeAPO, and
    摘要 在目前的工作中,3-methyl-4-amino-3-penten-2-one, 3-MeAPO, 3-methyl-4-methylamino-3-penten-2- 的分子结构和分子内氢键 (IHB)一, 3-Me-MeAPO, 和 3-methyl-4-phenylamino-3-penten-2-one, 3-Me-PhAPO 已经通过密度泛函理论 (DFT) 计算研究, 在 B3LYP/6 -311++G** 水平,以及包括核磁共振、红外、拉曼、紫外光谱和 X 射线晶体学方法在内的实验研究。将上述结果与 4-amino-3-penten-2-one, APO 的结果进行比较。DFT 计算表明 3-MeAPO 及其 N Me 和 N-Ph 取代衍生物中存在相对强的分子内氢键,N⋯O 距离为 2.597、2.584 和 2.581 A,计算出的氢键能约为 10.9、13.6 和
查看更多